We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Rockwell Medical Inc (RMTI) Common Stock NPV

Sell:$0.40 Buy:$0.42 Change: $0.0221 (5.20%)
Market closed |  Prices as at close on 1 December 2021 | Switch to live prices |
Change: $0.0221 (5.20%)
Market closed |  Prices as at close on 1 December 2021 | Switch to live prices |
Change: $0.0221 (5.20%)
Market closed |  Prices as at close on 1 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Rockwell Medical, Inc. is a commercial-stage, biopharmaceutical company. The Company is developing and commercializing its technology platform, Ferric Pyrophosphate Citrate (FPC) for the transformative treatments for iron deficiency in multiple disease states. It is also a supplier of hemodialysis concentrate products to kidney dialysis clinics. The Company has developed therapies namely Triferic and Triferic AVNU from its FPC platform. The Company’s products from its FPC platform, Triferic (dialysate) and Triferic AVNU intravenous (IV), is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients. Its Triferic AVNU, is an IV formulation of Triferic, for use by hemodialysis patients. its dialysis concentrates products include CitraPure Citric Acid Concentrate, Dri-Sate Dry Acid Concentrate, RenalPure Liquid Acid Concentrate, Dry Acid Concentrate Mixer, RenalPure and SteriLyte Bicarbonate Concentrate and Ancillary products.

Contact details

United States
+1 (248) 9609009

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$39.94 million
Shares in issue:
93.97 million
Health Care Supplies
United States
US dollar

Key personnel

  • Russell Ellison
    President, Chief Executive Officer, Director
  • Russell Skibsted
    Executive Vice President, Chief Financial Officer, Chief Business Officer
  • Paul McGarry
    Principal Accounting Officer, Vice President, Corporate Controller
  • Michael DeYoung
    Vice President - Operations
  • Marc Hoffman
    Chief Medical Officer
  • Raymond Pratt
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.